BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 117 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,062,680 | +2.7% | 2,551,226 | +2.2% | 0.48% | +15.8% |
| Q2 2023 | $17,580,239 | -9.7% | 2,497,193 | +7.0% | 0.42% | -9.9% |
| Q1 2023 | $19,466,269 | -10.3% | 2,334,085 | +23.4% | 0.46% | -11.1% |
| Q4 2022 | $21,705,661 | +0.6% | 1,890,737 | +10.4% | 0.52% | -6.3% |
| Q3 2022 | $21,578,000 | +39.6% | 1,712,507 | +17.2% | 0.56% | +23.8% |
| Q2 2022 | $15,458,000 | +171.3% | 1,461,091 | +108.7% | 0.45% | +104.5% |
| Q1 2019 | $5,698,000 | +0.9% | 700,000 | 0.0% | 0.22% | -17.6% |
| Q4 2018 | $5,649,000 | +5.8% | 700,000 | 0.0% | 0.27% | +38.3% |
| Q3 2018 | $5,341,000 | +272.7% | 700,000 | +180.0% | 0.19% | +250.9% |
| Q2 2018 | $1,433,000 | -67.5% | 250,000 | -73.0% | 0.06% | -70.7% |
| Q1 2018 | $4,412,000 | +10.6% | 925,000 | +13.8% | 0.19% | +3.9% |
| Q4 2017 | $3,989,000 | +69.2% | 812,500 | +80.6% | 0.18% | +66.1% |
| Q3 2017 | $2,358,000 | – | 450,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |